Antihypertensive polytherapy was associated with lower all-cause mortality risk than monotherapy in metastatic breast cancer, notably among Hispanic women.
Does antihypertensive polytherapy reduce all-cause mortality in patients with metastatic breast cancer compared to monotherapy?
Antihypertensive polytherapy is associated with improved survival in patients with metastatic breast cancer compared to monotherapy, particularly among Hispanic women.
Absolute Event Rate: 0% vs 0%
In patients with mBC, all-cause mortality risk was lower among those treated with antihypertensive polytherapy versus monotherapy, with the greatest risk attenuation seen among Hispanic women. Additional prospective studies are needed to examine comorbidity management strategies that may help patients with mBC extend life, particularly including women of color.
Haque et al. (Sun,) reported a other. Antihypertensive polytherapy was associated with lower all-cause mortality risk than monotherapy in metastatic breast cancer, notably among Hispanic women.